Crossmark

Cost-Effectiveness Analysis of Pharmaceutical-Grade Chondroitin Sulfate for Knee Osteoarthritis Based on Individual Patient Data from a Randomized Clinical Trial

Crossref DOI link: https://doi.org/10.1007/s12325-024-03007-4

Published Online: 2024-10-30

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bruyère, Olivier https://orcid.org/0000-0003-4269-9393
Reginster, Jean-Yves
Funding

Funding for this research was provided by:

IBSA (SOP008)
License Information

Text and Data Mining valid from 2024-10-30

Version of Record valid from 2024-10-30
More Information

Article History

Received: 5 July 2024

Accepted: 20 September 2024

First Online: 30 October 2024

Declarations

:

: Olivier Bruyère and Jean-Yves Reginster have received consulting or lecture fees from IBSA outside the submitted work. Olivier Bruyère and Jean-Yves Reginster are Editorial Board members of Advances in Therapy. Olivier Bruyère and Jean-Yves Reginster were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This trial was designed and monitored in accordance with the ethical principles of the International Conference on Harmonisation (ICH), the Consolidated Guideline on Good Clinical Practice (GCP), in accordance with the Declaration of Helsinki and following all other requirements of local laws. Ethics committee approval from all participating centres was obtained and all patients gave their written informed consent to participate. The central ethics committee was the Comite d’Ethique Hospitalo-Facultaire Universitaire de Liege in Belgium.

Document is current

Any future updates will be listed below